← Leaderboards
Quintin Pan
University Of Michigan At Ann Arbor
$6,742,395
Attributed
$8,762,575
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,762,575 · 5
By mechanism
R01$8,762,575 · 5
Top collaborators
- Paramjit S Arora10 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Maureen Agnes Sartor$7,415,011
- Thomas E. Carey$14,226,111
- Nisha J D'silva$14,161,982
- Weiping Zou$38,970,401
- James J. Moon$14,172,333
Others in their field
Top investigators on “Head And Neck Squamous Cell Carcinoma”
- Jennifer R Grandis · University Of Pittsburgh At Pittsburgh$17,047,548
- Cun-Yu Wang · University Of California Los Angeles$14,843,475
- Lorraine J Gudas · Sloan-Kettering Institute For Cancer Res$11,559,006
- Qingyi Wei · University Of Texas Md Anderson Can Ctr$11,102,171
- Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh$10,353,289
- Xiao-Jing Wang · University Of California At Davis$9,895,933
Research focus
Head And Neck Squamous Cell CarcinomaCellsDesignOropharyngealEp300 GeneMalignant NeoplasmsResponseHuman PapillomavirusIncidenceMorbidity - Disease RateLeadCisplatinPhenotypeProteinsRisk FactorsRadiationUnited StatesHuman Papillomavirus 16Novel TherapeuticsBaseInnovationPublic Health RelevanceBiologicalIn Vitro
Grant awards (23)
Dual p300 and p53 reactivation in HPV+ head and neck cancer$562,898
R01 · FY2025 · DE · contact PI
Dual p300 and p53 reactivation in HPV+ head and neck cancer$575,570
R01 · FY2024 · DE · contact PI
Cancer Initiating Cells and Treatment Resistance$353,319
R01 · FY2020 · CA · contact PI
Role of P300 in HPV-positive Head and Neck Cancer$487,899
R01 · FY2019 · DE · contact PI
p53/Rb Reactivation Modulators for HPV-positive Head and Neck Cancer$360,524
R01 · FY2019 · GM
Role of P300 in HPV-positive Head and Neck Cancer$504,629
R01 · FY2018 · DE · contact PI
Cancer Initiating Cells and Treatment Resistance$368,551
R01 · FY2018 · CA · contact PI
p53/Rb Reactivation Modulators for HPV-positive Head and Neck Cancer$360,524
R01 · FY2018 · GM
p53/Rb Reactivation Modulators for HPV-positive Head and Neck Cancer$125,000
R01 · FY2018 · GM
Role of p300 in HPV-positive Head and Neck Cancer$481,034
R01 · FY2017 · DE · contact PI
p53/Rb Reactivation Modulators for HPV-positive Head and Neck Cancer$360,524
R01 · FY2017 · GM
Cancer Initiating Cells and Treatment Resistance$349,648
R01 · FY2017 · CA · contact PI
Role of p300 in HPV-positive Head and Neck Cancer$485,789
R01 · FY2016 · DE · contact PI
p53/Rb Reactivation Modulators for HPV-positive Head and Neck Cancer$375,149
R01 · FY2016 · GM
Cancer Initiating Cells and Treatment Resistance$349,785
R01 · FY2016 · CA · contact PI
Role of p300 in HPV-positive Head and Neck Cancer$499,289
R01 · FY2015 · DE · contact PI
Cancer Initiating Cells and Treatment Resistance$363,417
R01 · FY2015 · CA · contact PI
Role of PKCepsilon in Oral Cancer$301,913
R01 · FY2012 · CA · contact PI
Role of PKCepsilon in Oral Cancer$301,913
R01 · FY2011 · CA · contact PI
Role of PKCepsilon in Oral Cancer$311,250
R01 · FY2010 · CA · contact PI
Role of PKCepsilon in Oral Cancer$311,250
R01 · FY2009 · CA · contact PI
Role of PKCepsilon in Oral Cancer$311,250
R01 · FY2008 · CA · contact PI
Role of PKCepsilon in Oral Cancer$261,450
R01 · FY2008 · CA · contact PI